Related references
Note: Only part of the references are listed.Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes
Kentaro Konishi et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
Mohamad Shebley et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives
Monique Groen-Wijnberg et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
Phase III, randomised, double-blind, placebo-controlled study of the 3-adrenoceptor agonist mirabegron, 50mg once daily, in Japanese patients with overactive bladder
Osamu Yamaguchi et al.
BJU INTERNATIONAL (2014)
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol
Walter Krauwinkel et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2014)
Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron
James Dickinson et al.
CLINICAL DRUG INVESTIGATION (2013)
Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist
Jennifer Lee et al.
CLINICAL DRUG INVESTIGATION (2013)
Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
Vik Khullar et al.
EUROPEAN UROLOGY (2013)
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
V. W. Nitti et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Intestinal Absorption Mechanism of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems
Shin Takusagawa et al.
MOLECULAR PHARMACEUTICS (2013)
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
Sender Herschorn et al.
UROLOGY (2013)
A Decade After the KDOQI CKD Guidelines
Andrew S. Levey
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women
Walter Krauwinkel et al.
CLINICAL THERAPEUTICS (2012)
Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist
Shin Takusagawa et al.
XENOBIOTICA (2012)
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Malcolm Rowland et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Clinical Pharmacokinetics of Metformin
Garry G. Graham et al.
CLINICAL PHARMACOKINETICS (2011)
Modeling and predicting drug pharmacokinetics in patients with renal impairment
Karen Rowland Yeo et al.
Expert Review of Clinical Pharmacology (2011)
Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications
Y. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Influence of Chronic Renal Failure on Drug Metabolism and Transport
A. W. Dreisbach
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Simcyp® Population-based ADME Simulator
Masoud Jamei et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Emerging evidence of the impact of kidney disease on drug metabolism and transport
T. D. Nolin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Prevalence of chronic kidney disease in the United States
Josef Coresh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function
Toshiyuki Takasu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Effects of renal failure on drug transport and metabolism
H Sun et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
AS Levey et al.
KIDNEY INTERNATIONAL (2005)
Kidney disease as a risk factor for development of cardiovascular disease - A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention
MJ Sarnak et al.
HYPERTENSION (2003)
Share Paper
